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In the current issue of the Journal of Thoracic Oncology, Murray et al.1 provide ananalytical database of somatic mutations of the epidermal growth factor receptor
(EGFR) tyrosine kinase (TK) domain. The authors catalogue data from 3181 patients (of
12,444 screened) with somatic mutations of the EGFR. Most of these mutations occur at
a very low rate, including 62.2% that were reported on only one occasion. The two most
common mutations are L858R and delE746-A750, representing 32.84% and 24.28% of all
reported mutations, respectively. Overall the L858R and deletion mutations in exon 19
represent about 90% of all mutations. It is also reported that tumor response to EGFR TK
inhibitors depends on mutational type. For example, mutations in exon 19 and 20 result
in response rates to EGFR TK inhibitors of 86% and 33.3%, respectively. Although most
of the identified mutations are associated with a favorable response to treatment, a small
fraction is also associated with nonresponse.
The discovery of mutations in the EGFR TK domain was initially reported by Lynch
et al. and Paez et al. 2,3 over 4 years ago. These investigators identified key mutations that
portend sensitivity of cancer cells to gefitinib. Soon thereafter, Pao et al. 4 reported similar
observations with erlotinib. These molecular discoveries helped explain the clinical
observations that never smokers, those with adenocarcinoma, females, and those of Asian
descent appeared to benefit most from EGFR TK inhibitors. This landmark research brings
us closer to realizing individualized care for patients suffering from lung cancer. The
history of cancer care has been previously dominated by observational discovery, resulting
in the development of most of the cornerstone chemotherapy drugs from the 1950s
through the 1990s. The empiric combination of these drugs that had single agent activity,
preclinical additivity or synergism, nonoverlapping toxicities, and the ability to give in full
dosages marked the key strategies of the last four decades against nearly all malignancies.
As the plateau in survival with chemotherapy strategies are realized, we are now
experiencing a paradigm shift in drug discovery and strategies against cancer.
Interest in the study of the EGFR signaling pathway has intensified over the last few
years. Since the initial reports regarding EGFRmutations, others have reported the importance
of EGFR gene copy number as a predictor for response and survival with EGFR TK
inhibitors.5 In addition, three markers for EGFR TK resistance have been identified; namely,
T790 mutations in exon 20 (resulting in a conformational change in the binding site for EGFR
TK inhibitors), c-met amplification (increasing downstream signaling through ERBB3), and
KRAS mutations.6–8 Much is still unknown about EGFR sensitivity and resistance. Only
about 10% of patients with non-small cell lung cancer harbor EGFR mutations and, while
highly predictive of tumor response to EGFR TK inhibitors, data from one randomized trial
comparing erlotinib versus placebo failed to show a survival benefit for those with EGFR
mutations treated with erlotinib.9 Results from another trial indicated that those with any
EGFR mutations had better outcomes, regardless of therapy administered (chemotherapy
with/without erlotinib).8 In this same study, a subset of patients with exon 19 deletions had
better outcomes compared with patients harboring L858R mutations.10 Similarly, although
increased gene copy number of EGFR is highly predictive of response and survival with
EGFR TK inhibitors, a recent comparison of docetaxel and gefitinib failed to demonstrate a
survival benefit for those receiving gefinitib who had increased gene copy number.11 This data
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suggests that increased gene copy number may also predict for
benefits with chemotherapy. So, do EGFR mutations also pre-
dict for response to chemotherapy? Perhaps not, as Suehisa et
al.12 report no benefit for adjuvant uracil-tegafur in patients with
EGFR mutations that undergo surgical resection, whereas those
with wild-type EGFR appeared to have prolonged survival.
Although our understanding of the molecular biology
of the EGFR pathway is unfolding, we remain challenged by
the genetic complexities of lung cancer (of the known and
unknown). This point is underscored by Davies et al.13 who
identified 518 previously unreported mutations in receptor
TKs from 26 lung cancers and 7 lung cancer cell lines. The
majority of these are passenger mutations and not dominant
drivers of cancer growth. Others have reported the genetic
complexities of lung cancer to exceed those of almost any
other solid tumor.14 Identification of gene mutations is a key
step to solving the biologic puzzle of lung cancer; however,
with each clue uncovered, more questions are generated. For
example, Riely and colleagues recently reported differential
types of mutations involving KRAS observed in smokers
versus never smokers.15 Will this mean that mutation type for
KRAS will also predict for differential response to EGFR
inhibitors?
Having gathered a significant database regarding EGFR
mutations and other predictors of response or resistance to
EGFR inhibitors, what is next? It is likely that similar
discoveries will be made in other cell signaling pathways
important in the pathogenesis of lung caner. Targeting a
single aberrant pathway is unlikely to have a substantial
effect on a genetically diverse disease like lung cancer. More
likely, we will learn to combine targeted agents in a rationale
manner, tailored for an individual based on their tumor
characteristics. If successful, we will be able to finally reduce
the suffering and dying from this dreaded disease.
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